Home › Trials › NCT06999603

Inhaled SNG001 for mechanically ventilated patients with viral pneumonia

A Phase 2, Two-part Study to Assess the Safety, Antiviral Biomarker Responses, and Efficacy of Inhaled SNG001 for the Treatment of Patients With a Confirmed Respiratory Virus Infection Undergoing Invasive Mechanical Ventilation

Phase 2 Interventional Synairgen Research Ltd. · NCT06999603

This study will test whether inhaled SNG001, given once daily with standard care, can help clear virus faster and reduce deaths in adults on ventilators for viral pneumonia.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment550 (estimated)
Ages18 Years and up
SexAll
SponsorSynairgen Research Ltd. Industry-sponsored
Drugs / interventionsalemtuzumab, Ibrutinib, Chimeric antigen receptor, chemotherapy, Methotrexate, prednisone
Locations67 sites (Sacramento, California and 66 other locations)
Trial IDNCT06999603 on ClinicalTrials.gov

What this trial studies

This randomized, placebo-controlled Phase 2 study gives all participants standard of care plus either inhaled SNG001 or placebo once daily for up to 14 days while hospitalized and mechanically ventilated for a confirmed respiratory viral infection. The trial is split into two parts: Part 1 focuses on safety in patients aged 50 and older, and Part 2 evaluates efficacy in adults over 50 (with or without immunocompromise) and immunocompromised adults aged 18–50. Eligible patients must have a positive rapid respiratory virus test and receive the first dose within 48 hours of intubation. Outcomes include safety, antiviral biomarker responses, time to virus clearance, and mortality compared with standard of care.

Who should consider this trial

Good fit: Adults admitted to participating ICUs with confirmed respiratory viral pneumonia who require invasive mechanical ventilation and can receive the first study dose within 48 hours of intubation are the intended participants.

Not a fit: People who are not mechanically ventilated, those without a confirmed respiratory viral infection, or those beyond 48 hours after intubation are unlikely to benefit from this study intervention.

Why it matters

Potential benefit: If successful, SNG001 could shorten time to viral clearance and reduce mortality among patients on mechanical ventilation for viral pneumonia.

How similar studies have performed: Previous small studies of inhaled interferon beta (SNG001) in hospitalized viral respiratory infections have reported promising antiviral and clinical signals, but large-scale confirmatory evidence is limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Part 1 Inclusion Criteria:

To be eligible for randomisation into Part 1 of this study, each participant must fulfil the following criteria:

1. Informed consent or legal representative's consent obtained.
2. Patients ≥50 years of age at the time of consent.
3. Patient admitted to the ICU and requiring invasive mechanical ventilation (IMV) due to a respiratory virus infection.
4. Presence of Influenza A (Flu A), Influenza B (Flu B), respiratory syncytial virus (RSV), rhinovirus (RV), adenovirus, parainfluenza, human metapneumovirus (HMPV), or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a nose swab sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., reverse transcription polymerase chain reaction \[RT-PCR\]).
5. Time from intubation to administration of first dose of study medication ≤48 hours.
6. Women of childbearing potential must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \<55 years old.

Part 1 Exclusion Criteria:

A participant must not be randomised into Part 1 of the study if they meet any of the following criteria:

1. Expected termination of IMV within 24 hours from the time of randomisation
2. Life expectancy \<24 hours.
3. Liver failure (Child-Pugh C).
4. Severe congestive heart failure (New York Heart Association \[NYHA\] IV).
5. Receipt of lung transplant.
6. Known or suspected active tuberculosis, or infection with other mycobacteria
7. Known or suspected active systemic fungal infection.
8. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.
9. Need for long-term mechanical ventilation prior to ICU admission.
10. Use of inhaled sedation.
11. Presence of tracheostomy or laryngectomy.
12. Requirement for airway pressure release ventilation mode.
13. History of hypersensitivity to natural or recombinant IFNβ or to any of the excipients in the drug preparation.
14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
15. Participation in previous clinical studies of SNG001.
16. Current or previous participation in another clinical study where the participant has received a dose of an Investigational Medicinal Product (IMP) containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
17. Known or suspected pregnancy.
18. Females who are breast-feeding or lactating.
19. Immunocompromising condition, including:

    * Established acquired immune deficiency syndrome (AIDS) defined as a cluster of differentiation 4 (CD4) count \<200 cells/microL, and/or the presence of any AIDS-defining condition;
    * Haematological malignancy;
    * Bone marrow transplantation; or
    * Immunosuppressive therapy, including:
    * Cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy), immune-cell depleting therapy, immunosuppressive therapy for autoimmune disorders, medications for prevention of organ transplantation rejection, administered within 6 months prior to randomisation; or
    * Corticosteroids \>20 mg of prednisone or equivalent per day administered continuously for \>14 days prior to randomisation.
20. Severe chronic lung disease requiring home oxygen therapy, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis.

Part 2 Inclusion Criteria:

To be eligible for randomisation into Part 2 of this study, each participant must fulfil the following criteria:

1.a Patients ≥18 and \<50 years of age at the time of consent, with an immunocompromising condition, including:

* Solid tumour malignancy undergoing cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy);
* Haematological malignancy in remission, with or without maintenance therapy;
* Immunosuppressive therapy for autoimmune disease;
* Therapy for prevention of organ transplant rejection;
* Corticosteroids \>20 mg of prednisone or equivalent per day, administered continuously for \>14 days prior to randomisation or

  1. b Patients ≥50 years of age at the time of consent, with or without an immunocompromising condition (as defined above).
  2. Patient admitted to the ICU and requiring IMV due to a respiratory virus infection.
  3. Presence of Flu A, Flu B, RSV, RV, adenovirus, parainfluenza, HMPV, or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a Lower Respiratory Tract sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., RT-PCR).
  4. Time from intubation to administration of first dose of study medication ≤48 hours.
  5. Informed consent or legal representative's consent obtained.
  6. Women of childbearing potential must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \<55 years old.

Part 2 Exclusion Criteria:

A participant must not be randomised into Part 2 of the study if they meet any of the following criteria:

1. Expected termination of IMV within 24 hours from the time of randomisation.
2. Life expectancy \<24 hours.
3. Liver failure (Child-Pugh C).
4. Severe congestive heart failure (NYHA IV).
5. Receipt of lung transplant.
6. Known or suspected active tuberculosis, or infection with other mycobacteria.
7. Known or suspected systemic fungal infection.
8. Immunocompromising condition, including:

   * Haematological malignancy requiring induction or consolidation therapy within 3 months prior to randomisation;
   * Bone marrow transplant within 6 months prior to randomisation;
   * Solid organ transplant within 6 months prior to randomisation;
   * Corticosteroids \>75 mg of prednisone or equivalent per day, administered continuously for \>7 days prior to randomisation;
   * Methotrexate therapy at randomisation, if the indication is chemotherapy for cancer;
   * Chimeric antigen receptor (CAR)-T cell therapy, administered within 3 months prior to randomisation;
   * Ibrutinib or alemtuzumab, administered within 3 months prior to randomisation;
   * Neutropenia \<500/mm3 not due to sepsis;
   * Clinical presentation consistent with severe bone marrow suppression or pancytopenia;pancytopenia;
   * Established AIDS, defined as a CD4 count \<200 cells/microL, and/or the presence of any AIDS-defining condition.
9. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.
10. Need for long-term mechanical ventilation prior to ICU admission.
11. Use of inhaled sedation.
12. Presence of tracheostomy or laryngectomy
13. History of hypersensitivity to natural or recombinant IFNβ or to any of the excipients in the drug preparation.
14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
15. Participation in previous clinical studies of SNG001.
16. Current or previous participation in another clinical study where the participant has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
17. Known or suspected pregnancy.
18. Females who are breast-feeding or lactating.
19. Severe chronic lung disease requiring home oxygen therapy, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis

Where this trial is running

Sacramento, California and 66 other locations

+17 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Viral PneumoniaInfluenzaRespiratory Syncytial VirusRhinovirusAdenovirusHuman MetapneumovirusCoronavirusIntubated
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.